PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION
REQUESTS PROPOSALS FOR THERAPEUTIC TARGETS
Deadline (Cycle 2) November 2\textsuperscript{nd}, 2018

Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique collaboration that partners with leading academic medical centers to rapidly translate novel target opportunities into new medicines.

CTI Collaborations may include
- Funded project-related research
- Hands-on partnering from dedicated Pfizer drug-development experts
- Collaborative use of Pfizer’s science and technologies
- Financial incentives in the form of milestone and royalty payments for successful programs
- Flexible publishing rights
- Involvement of CTI’s Foundation alliances

Modalities Considered
- **Large Molecules**: antibodies, proteins, fusion proteins, antibody conjugates
- **Small Molecules**: target classes include kinases, deubiquitinating enzymes, GPCRs, ion channels, solute transporters, and epigenetic targets

Areas of Interest
**Disease Area Focus:**
- **Cancer** – Select solid tumors, such as Colorectal, Breast, Lung (small cell and non-small cell), Pancreatic, Ovarian
- **Autoimmunity/Inflammation** – IBD, NAFLD/NASH, Atopic Dermatology, Psoriasis
- **Metabolic** - T2DM, Cachexia
- **Rare** - ALS, Huntington’s, Duchene’s or Becker’s muscular dystrophy, non-malignant haematological disorders

**Targets/Pathways Focus:**
- Immune Activators /Enhancers (e.g., nucleic acid sensing, TLRs, etc.)
- DNA Damage Recognition & Repair (e.g., replication stress or repair enzymes)
- Tissue–Resident Immune modulation (adaptive & innate, TME, organ specific, such as skin or gut)
- Modulation of tumor cell heterogeneity, senescence, plasticity (including drug resistance)
- Regulation of epithelial biology (i.e. restoring barrier health/integrity)
- Modulation of fibrosis pathways either metabolism/stress-induced, or inflammation-induced (possibly tumor-driven)
- Regulation of antigen-specific tolerance induction and/or modulation of T regulatory cells
- Treatments for repeat expansion diseases including Huntington’s disease, ALS/FTD and myotonic dystrophy
- Interventions to address skeletal and cardiac muscle diseases (including Duchenne or Becker muscular dystrophies)

Pre-proposal Submission Process
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

For Information
Please contact Mary Faris at mary.faris@pfizer.com and Amrit Shahzad at ashahzad@ucsd.edu 

All researchers and clinicians whose work meets these criteria are invited to apply. Please submit non-confidential pre-proposals to your Technology Transfer Office by November 2, 2018.